What is Candida antigen and bivalent HPV vaccine studying for warts?

This trial is evaluating how Candida antigen and bivalent HPV vaccine work alone or together to treat common warts. Researchers aim to understand their effects on wart clearance and recurrence. The study is sponsored by Zagazig University and involves careful monitoring of safety and effectiveness.

Who may be eligible for this warts clinical trial?

Participants must be at least 9 years old with multiple common warts of various sizes and locations. Both males and females can join unless pregnant or allergic to Candida antigen or the HPV vaccine. Please review eligibility criteria for more details.

Is there any cost to participate in this warts clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 2

Age: 9Years +

All Genders

ID05291845

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts Monotherapy Versus Combined Therapy

Led by Zagazig University · Updated on 2025-06-12

162

Participants Needed

Research Sites

9 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the safety and effectiveness of Candida antigen and bivalent HPV vaccine in treating common warts. The trial compares these treatments given alone or combined to see how well they clear warts and prevent recurrence. This is a Phase 2 randomized study involving patients with multiple warts. Participants are divided into three groups one receives Candida antigen injections directly into the largest wart, another receives bivalent HPV vaccine injections, and the third group receives both treatments together. Injections are given every two weeks for up to five sessions or until the warts clear. During the study, patients will be monitored for complete, partial, or no response to treatment over three months. Researchers will also follow up for six months after recovery to check for wart recurrence. Assessments include clinical evaluation of warts and treatment safety throughout the trial.

CONDITIONS

Brief Title

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Who Can Participate

Age: 9Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, and duration, with or without distant lesions

You will not qualify if you...

Pregnant female
Hypersensitivity to Candida antigen or bivalent HPV vaccine

Research Team

Reham Essam, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here